MedPath

Efficacy of Soulter Spotless Cream on reducing acne and acne scars

Phase 4
Completed
Conditions
Health Condition 1: L700- Acne vulgaris
Registration Number
CTRI/2021/09/036277
Lead Sponsor
PHARMADOCS
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
80
Inclusion Criteria

Subjects suffering from Acne Vulgaris and/or having acne scars. Participants willing to give written informed consent. Participants are fit and no need any hospital administration. Agree to following instruction of doâ??s and donâ??ts in regular daily lifestyle. Subjects willing to perform all study related procedures including the use of study oil, allow the physical and other tests and willing to document symptoms and medication. Subjects/ volunteers/ study participants {and /or legally accepted representative (LAR)} willing to give written informed consent and ability to adhere to dosing and visit schedules and meet study requirements.

Exclusion Criteria

Participants unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study. Inability to carry out visits for the study. Chronic & acute disorders requiring hospital admission. Known HIV-positive, Hepatitis B or C status. Volunteers/ study participants unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.

Study & Design

Study Type
PMS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in skin status w.r.t. acne vulgaris. <br/ ><br>Lightens acne scars. <br/ ><br> <br/ ><br>Clinical assessment- 15 days. <br/ ><br>Global Acne Grading System (GAGS)- 15 days. <br/ ><br>Investigator Global Assessment of acne (IGA)- 15 days. <br/ ><br>Cardiff Acne Disability Index (CADI)- 15 days. <br/ ><br>Dermatology Life Quality Index (DLQI)- 15 days. <br/ ><br>Safety Assessment Scale- 15 days. <br/ ><br>Postinflammatory Hyperpigmentation Severity Scale- 15 days. <br/ ><br>Timepoint: Clinical assessment- 15 days. <br/ ><br>Global Acne Grading System (GAGS)- 15 days. <br/ ><br>Investigator Global Assessment of acne (IGA)- 15 days. <br/ ><br>Cardiff Acne Disability Index (CADI)- 15 days. <br/ ><br>Dermatology Life Quality Index (DLQI)- 15 days. <br/ ><br>Safety Assessment Scale- 15 days. <br/ ><br>Postinflammatory Hyperpigmentation Severity Scale- 15 days. <br/ ><br> <br/ ><br> <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
Changes in quality of life (DLQI). <br/ ><br>Adverse Events. <br/ ><br> <br/ ><br>Timepoint: Changes in quality of life - DLQI - 15 days <br/ ><br>No incidence of Adverse events (AE) and Serious Adverse Events (SAE) during the study period - 15 days
© Copyright 2025. All Rights Reserved by MedPath